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Summary
The thrombin potential (TP) has been defined as the time
integral of (i. e. the area under) the thrombin generation curve. It
has been shown that this parameter decreases with all types of
anticoagulant treatment and increases with ATIII deficiency.
We evaluated the use of this parameter for detection of the
hypercoagulative state known to accompany oral contraception.
ln fresh frozen control plasma the TP could be determined with
high reproducibility (n : 82, c.v 2.9"/"). The TP was linearly
diminished by mixing fresh frozen plasma with prothrombin
deficient plasma while a high coefficient of correlation was
observed (r : 0.997).
Women using oral contraceptives showed a significantly
( p  < 0 . 0 0 0 1 )  h i g h e r T P  ( T P : 5 6 9 n M ' m i n ,  S D : 5 5 ,  n : 1 7 ) ,
compared to men or, to women not using oral contraceptives (TP
:  484 nM.min ,  SD :  52 ,  n :  4 l ) .
This suggests that the thrombin potential indicates the pre-
thrombotic state known to exist in women using oral contracep-
tlves.
Introduction
Overall coagulability is usually assessed by means of a clotting
time in one of its many variations. This always amounts to
measuring the lag time before a burst of thrombin occurs (l).
The clotting time gives no direct information, either on the
amount of thrombin generated or on the time during which it can
acI.
The Thrombin Generation Test has proven its value in the
laboratory research on the mode of action of anticoagulants (2-5).
It has been suggested that the time integral of the thrombin
generation curve, i.e. the area under that curve, would be a good
parameter for the amount of "enzymatic work" (haemostatic or
thrombotic) that thrombin generated in clotting blood can do (6,
7). This parameter has been called the thrombin potential (TP)
( 8 ) .
It has been shown (9-12) that the TP decreases as a result of
heparin treatment, with oral anticoagulation and by a variety of
other anticoagulants (Dermatan sulfate, Hirudin, Lactobionic
acid and various low molecular weight heparins). The thrombin
potential therefore, is candidate to become a general indicator of
hypocoagulability.
We wanted to investigate whether the thrombin potential
would be a practical test in a hospital laboratory, and whether it
could detect the relatively subtle hypercoagulative state that
accompanies the use of oral contraceptives (7). Therefore, we
evaluated the Thrombin Generation Test, using fresh frozen
human plasma, for reproducibility and linearity with respect to
prothrombin concentration. The distribution of TP values was
established for women using and not using oral contraceptives and
for men.
Mater ia ls and Methods
Volunteers
Informed consent was obtained from 58 apparently hcalthy volunteers
without any history of coagulation disorders.
The group consisted of 17 women using oral contraceptives (type sub-
50, estrogen: ethinyl estradiol), 18 women not using any and 23 men.
Two women, one from each group, wcrc followed for about one month
in order to see whether the TP varies during the menstrual cycle Blood
was sampled from the one taking oral contraceptives on days 1,2,8, 10,
20,27 of  the menstrual  cycle (28 days);  f rom the other on days 1,4,7,  12,
14,  I7.79 (cyclc 26 days).
Collection and Processing of Blood Samples
Blood was collected on 0 13 M trisodium citratc: nine parts of blood to
one part citratc solution. After centrifugation (2000 g, 20 min, room
temperature) the plasma was collected and whcn necessary stored at
-20' C until analysis All samples were analyzed for prothrombin time
(PT), activated partial thromboplastin time (aPTT), antithrombin III
(ATIID and thrombin potential (TP).
Reagents and Assays
Reptilase was obtained from Boehringer Mannhcim (Mannheim,
Germany), human thromboplastin from Behring (Behringwerke AG,
Markburg, France), Factor II deficient plasma from Laboratoires Stago
(Asnibres, France). Thrombin substrate 52238 came from Kabi Diagnos-
tica (Mdlndal, Sweden). All reagents were prepared according to the
manuf acturers' instruction
PT and aPTT values were obtained by mcans of Boehringer Mannheim
Calcium-Thromboplastin and PTT Reagent, no coagulometer was uscd
ATIII values were obtained by means of reagents from Kabi Diagnostica.
As control material, fiesh frozen ACD plasma was obtained fi'om thc
Central Laboratory of thc Bloodbank of Amsterdam
Thc fresh frozen plasma was derived from one donor, collectcd in
citrate anticoagulant with the same end-concentration as voluntecrs'test
plasmas. The frozcn material was allowed to reach room tempcrature in
about 5 h, thoroughly mixed, distributed in 1.5 ml portions and restored
at -20" C. All chemicals were of the highest grade commercially
availablc. All solutions wcrc made in 18 Mohm ' cm de-ionized water
Determination of Thrombin Generalion in Plasma
Dcfibrinated plasma was obtained by mixing plasma 50:1 with
reptilase solution, allowing clot formation for 10 min at31" C and keeping
the clotted plasma at 0" C for 10 min. The fibrin thus formed was removed
by winding on a small plastic spatula.
Thrombin potential values werc measured as described in (6) and
determined in duplicate.
Correspondence to : H. C. Hemker, Dcpt. of Biochemistry, University
of Limburs, 6200 MD Maastricht. The Netherlands
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Fig I Linearity with respect to prothrombin of fresh frozen control
plasma diluted wirh factor II deficient plasma
Sntistics
Statistical analysis was performed with Statgraph 5.0 software (Statisti-
cal Graphics Corporation, USA). Values are means (+ SD) unless stated
otherwise Least square linear regression analysis was used in order to
evaluate linearity. Different groups of volunteers were compared using
the Mann-Whitney U test. A p-value less than 0 01 was considered to be
significant
Results
Reproducibility
To evaluate the interassay reproducibility of the determination
of the thrombin potential we measured the TP of a fresh frozen
plasma 82 times over a period of 3 months.
The mean value was 541 (+ 16) nM.min with a coefficient of
variation of 2.9%. The intra-assay reproducibility was calculated
from the duplicates according to (13). The standard deviation of
the differences was 14 nM.min. which is 2.6o/".
Linearity with Respect to Prothrombin Concentration
As described in the introduction, the TP is diminished by all
known anticoagulants (6, 10-12). Ceteris paribus, it should be
linear with respect to the prothrombin concentration in plasma
(9). This assumption is implicit to the use of the area under the
thrombin generation curve as a means of prothrombin estimation
(ref. 14, p. 165, p.353). We performed this linearity experiment to
see whether the results from a research laboratory (9) were
reproducible in our hospital laboratory.
As a test of variable TP values we determined the TP in a series
of plasmas in which the prothrombin concentration was varied by
mixing a control and a prothrombin deficient plasma. See Fig. 1.
Linear regression analysis was close to the line of identity:
TP'r.u,u."d : 1.048 (+ 0'036) '  TP.*p"",.d - 6.744 (t 10.0).
The coefficient of correlation was 0.997.
Thrombin Potential During the Menstrual Cycle
To investigate any possible variance associated with the
menstrual cycle, blood was taken from two women, one taking
oral contraceptives, at different points in the menstrual cycle.
The TP time variance for both women during the menstrual
cycle remained within the 2SD range of the assay (Fig.2). The
coefficients of variation werc 3.3yo and2.9"/" resoectivelv.
Healthy Volunteers
Blood was taken from 58 healthy volunteers, forming three
groups: men (n : 23), women using oral contraceptives (n : l7)
and women not using oral contraceptives (n : 18).
The thrombin potential, Pl aPTT and AIIII values were
determined. The mean values are presented in Thble 1 and Fig.3.
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Fig.2 The thrombin potential during the menstrual cycle. Open circles
represent TP values of a woman not using oral contraceptives with a
menstrual cycle of 26 days. Closed circles represent TP values of a woman
taking sub-50 oral contraceptives. The broken lines represent 2 SD limits
derived from reproducibility experiments (SD : 16 nM.min)
Linearity with Respect to Prothrombin Concentration
Linearity experiments were performed with defibdnated control ACD
plasma mixed with defibrinated factor II deficient plasma in order to get
dellned ratios of prothrombin concentration and minimal changes in othcr
plasma proteins. Expected values werc calculated from the TP of the
undiluted control matcrial, determined .+ times, and the dilution factor
TP values of mixed plasmas were mcasured in duplicate.
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Thble I Mean thrombin potential, P! aPTT and ATIII values of threc groups of volunteers; men women not using and using oral contraception
TP (SD)
n M . m i n
Pr (sD)
S
APTT (sD)
S
Arrrr (sD)
%
Men and women NOC 4I
Men
Women NOC
Women OC
484 (s2)
470 (48)
s01 (s4)
569 (55)**
1 3 4 ( 0 4 )
13.6  (0 .8 )
13.1 (0.6)
t2 e (0.7)
3s.7 (3.2)
36.s (3.2)
34.7 (3 o)
3s.3 (2.e)
126 (71)
1r8 (1s)
733 (17)*
r14 (r7)
18
I7
OC: using oral anticonceptives; NOC: not using oral anticonceptives.
+ p <0.01 comparing women not using oc. with women using oc and mcn
** p (0 0001 comparing women using oc. with women not using oc and men
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Flg.3 Thrombin potential values of men (n : 32), women not using
(female [-]) (" : 18) and women using oral contraceptives, (female [+])(n : L7). The mean TP for each group is indicated by a line * p <0 0001
comparing female (+) with female (-) and men.
Discussion
Given the central role of the enzymatic action of thrombin in
haemostasis and thrombosis, one can assume that the concentra-
tion of free thrombin in plasma together with the time during
which it is enzymatically active is the most important indication of
hyper- or hypocoagulability of a plasma sample.
The global activity of the clotting system is generally measured
by a clotting time, i.e. the time it takes to form a given
concentration of thrombin (1). This time may or may not
correlate with the amount of free thrombin generated. Usually
conditions are chosen so that is does, but up to now different tests
are needed for different situations. For instance, two tests are
needed to monitor the two types of anticoagulation, heparin and
vitamin K antagonists, although both anticoagulants diminish
thrombin enzymatic activity. In addition, some anticoagulants
(e.g. dermatan sulphate) escape detection by any current type of
clotting tests.
The Thrombin Generation Test monitors the end result of
thrombin formation and inactivation processes. Notably the
concentration-time integral of the thrombin generation curve will
reflect the amount of "enzymatic work" that generated thrombin
can carry out. It has been shown that a decreased thrombin
potential accompanies both heparin administration and treatment
of vitamin K antagonists (9-12).
We investigated whether the thrombin generation test could
detect the hypercoagulative state known to accompany the use of
oral contraceptives. We found a good inter- and intra-assay
reproducibi l i ty (c.v. resp. 2.9%,2.6%). We expect this result to
improve with a fully automated assay. The linearity of the assay
with respect to prothrombin was evident in the near-identity line
found in the regression analysis of the diluted samples.
From the finding that the TP varianpe during the menstrual
cycle was within the 2 SD uncertainty of the assay, we concluded
that the monthly cycle was of no significant influence on the Tp
(F ig .2 ) .
The thrombin potential is indeed influenced by use of oral
contraceptives; the TP increases (p <0.0001) (Fig.3).
To our knowledge, the Thrombin Generation Test seems to be
the first overall coagulation assay that can monitor the throm-
bogenic action of oral contraceptives (15 and references therein).
The procoagulant effect of oral contraceptives was not
reflected in PT or aPTT values. Conforming literature (15-18) we
found a lower mean ATIII value in women using oral contracep-
tives (Table 1). Future experiments will show whether there is a
relation between ATIII concentrations and TP values. In contrast
to ref. 15, no statistical difference was observed between ATIII
values of women using oral contraceptives and men.
Haemostasis is regulated by the delicate balance between
procoagulant and anticoagulant mechanisms. Disturbance in this
balance may lead to excessive bleeding tendency or increased risk
of thrombosis.
It seems that the TP reliably indicates small changes in this
balance.
On the other hand there is also the balance between fibrin
formation and degradation, which may be disturbed as well in
persons using oral contraceptives. Recently it has been reported
(19) that plasminogen levels are significantly higher in pill-taking
females (n : 694) compared to men (n : 5506) or non pill-taking
females (n : I72\.
In females taking oral contraceptives the phenomenon of a
higher plasminogen level might reflect a compensatory reaction to
a higher thrombin potential; nature's attempt to maintain the
balance in fibrin-forming and fibrin-degradation processes. We
think the TP does not reflect this balance.
Further studies will have to show whether the TP has any
predictive value for the occurrence of thrombosis.
We conclude that a coagulation test which demonstrates an
increased coagulability in a group of women using oral contracep-
tives, known to induce a mild prothrombotic tendency, is a
promising tool in determining the hitherto relatively elusive
"hypercoagulant state" that may predict a thrombotic tendency.
For routine use in coagulation laboratories this test need to be
automated, e.g. by continuous registration of thrombin amido-
lytic activity (20).
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